Related Experiment Video

Updated: Apr 28, 2026

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

10.6K

The neurohumoral axis in congestive heart failure

G S Francis, S R Goldsmith, T B Levine

    Annals of Internal Medicine
    |September 1, 1984
    PubMed

    Insights

    Congestive heart failure involves increased vasoconstrictor substances like norepinephrine and angiotensin II. New therapies aim to block these vasoconstrictor forces for better heart failure management.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Congestive heart failure (CHF) incidence is rising in the US.
    • CHF involves impaired ventricular function and increased vasoconstrictor substances such as norepinephrine, angiotensin II, and arginine vasopressin.
    • While compensatory, these systems may contribute to CHF pathogenesis, burdening the myocardium.

    Purpose of the Study:

    • To explore the role of vasoconstrictor systems in heart failure.
    • To review emerging therapeutic strategies targeting vasoconstriction in CHF.

    Main Methods:

    • Review of existing data on vasoconstrictor system activation in heart failure.
    • Analysis of preliminary findings for novel therapeutic interventions.

    Main Results:

    • Selective blockade of the renin-angiotensin system shows therapeutic utility in CHF.
    • Inhibition of the sympathetic nervous system shows potential benefit.
    • Vasopressin inhibition is under investigation in animal models of heart failure.

    Conclusions:

    • Excessive vasoconstriction exacerbates heart failure.
    • Targeting vasoconstrictor forces offers promising new therapeutic avenues for CHF.
    • Further research into selective blockade of these systems may lead to improved heart failure treatments.

    More Related Videos

    Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats06:30

    Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

    Published on: September 11, 2018

    7.4K
    Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis04:05

    Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

    Published on: June 30, 2023

    3.0K

    Related Concept Videos

    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    4.7K
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    1.9K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.7K
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    2.6K
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    1.7K
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    621